Large cell anaplastic medulloblastoma metastatic to the scalp: tumor and derived stem-like cells features

[1]  A. Gulino,et al.  High-throughput microRNA profiling of pediatric high-grade gliomas , 2013, Neuro-oncology.

[2]  M. Remke,et al.  Medulloblastoma molecular dissection: the way toward targeted therapy , 2013, Current opinion in oncology.

[3]  David T. W. Jones,et al.  Subgroup-specific prognostic implications of TP53 mutation in medulloblastoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  R. Gilbertson,et al.  A molecular biology and phase II trial of lapatinib in children with refractory CNS malignancies: a pediatric brain tumor consortium study , 2013, Journal of Neuro-Oncology.

[5]  B. Devi,et al.  Subcutaneous metastasis in medulloblastoma: A case report and review of literature , 2013, Journal of pediatric neurosciences.

[6]  V. Marquez,et al.  Inhibition of EZH2 suppresses self-renewal and induces radiation sensitivity in atypical rhabdoid teratoid tumor cells. , 2013, Neuro-oncology.

[7]  Scott L. Pomeroy,et al.  Medulloblastomics: the end of the beginning , 2012, Nature Reviews Cancer.

[8]  J. Barnholtz-Sloan,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. , 2012, Neuro-oncology.

[9]  P. Northcott,et al.  Targeting the enhancer of zeste homologue 2 in medulloblastoma , 2012, International journal of cancer.

[10]  Matthew J. Betts,et al.  Dissecting the genomic complexity underlying medulloblastoma , 2012, Nature.

[11]  Steven J. M. Jones,et al.  Subgroup-specific structural variation across 1,000 medulloblastoma genomes , 2012, Nature.

[12]  Jill P. Mesirov,et al.  MEDULLOBLASTOMA EXOME SEQUENCING UNCOVERS SUBTYPE-SPECIFIC SOMATIC MUTATIONS , 2012, Nature.

[13]  Stefan M. Pfister,et al.  The clinical implications of medulloblastoma subgroups , 2012, Nature Reviews Neurology.

[14]  S. Scherer,et al.  Clonal Selection Drives Genetic Divergence of Metastatic Medulloblastoma , 2012, Nature.

[15]  Scott L. Pomeroy,et al.  Molecular subgroups of medulloblastoma: the current consensus , 2011, Acta Neuropathologica.

[16]  Scott L. Pomeroy,et al.  Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples , 2011, Acta Neuropathologica.

[17]  J. Mesirov,et al.  Integrative genomic analysis of medulloblastoma identifies a molecular subgroup that drives poor clinical outcome. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[18]  Hendrik Witt,et al.  Medulloblastoma comprises four distinct molecular variants. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  Jeffrey T. Chang,et al.  Using a stem cell-based signature to guide therapeutic selection in cancer. , 2011, Cancer Research.

[20]  D. Ellison,et al.  Rapid Diagnosis of Medulloblastoma Molecular Subgroups , 2011, Clinical Cancer Research.

[21]  A. Paulino,et al.  Prognostic factors after extraneural metastasis of medulloblastoma. , 2010, International journal of radiation oncology, biology, physics.

[22]  Mauro Biffoni,et al.  Hedgehog controls neural stem cells through p53‐independent regulation of Nanog , 2010, The EMBO journal.

[23]  V. Santosh,et al.  Recurrence in medulloblastoma – Influence of clinical, histological and immunohistochemical factors , 2010, British journal of neurosurgery.

[24]  M. Shago,et al.  Universal poor survival in children with medulloblastoma harboring somatic TP53 mutations. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  W. Hartmann,et al.  Large cell/anaplastic medulloblastoma: Outcome according to myc status, histopathological, and clinical risk factors , 2010, Pediatric blood & cancer.

[26]  F. Giangaspero,et al.  Antitumor effect in medulloblastoma cells by gefitinib: Ectopic HER2 overexpression enhances gefitinib effects in vivo. , 2009, Neuro-oncology.

[27]  Axel Benner,et al.  Outcome prediction in pediatric medulloblastoma based on DNA copy-number aberrations of chromosomes 6q and 17q and the MYC and MYCN loci. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  A. Farcomeni,et al.  MicroRNA profiling in human medulloblastoma , 2009, International journal of cancer.

[29]  A. Regev,et al.  An embryonic stem cell–like gene expression signature in poorly differentiated aggressive human tumors , 2008, Nature Genetics.

[30]  B. Scheithauer,et al.  The 2007 WHO Classification of Tumours of the Central Nervous System , 2007, Acta Neuropathologica.

[31]  T. Merchant,et al.  Risk-adapted craniospinal radiotherapy followed by high-dose chemotherapy and stem-cell rescue in children with newly diagnosed medulloblastoma (St Jude Medulloblastoma-96): long-term results from a prospective, multicentre trial. , 2006, The Lancet. Oncology.

[32]  P. Burger,et al.  Phase III study of craniospinal radiation therapy followed by adjuvant chemotherapy for newly diagnosed average-risk medulloblastoma. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  C. Dang,et al.  c-myc overexpression causes anaplasia in medulloblastoma. , 2006, Cancer research.

[34]  M Galarza,et al.  Pure subcutaneous seeding from medulloblastoma. , 2003, Pediatric neurology.

[35]  R. McLendon,et al.  MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Children's Oncology Group. , 2002, Archives of pathology & laboratory medicine.

[36]  P. Burger,et al.  Comparative Genomic Hybridization Detects An Increased Number of Chromosomal Alterations in Large Cell/Anaplastic Medulloblastomas , 2002, Brain pathology.

[37]  J. Montebello,et al.  Intense P53 Staining is a Valuable Prognostic Indicator for Poor Prognosis in Medulloblastoma/central Nervous System Primitive Neuroectodermal Tumors , 2001, Journal of Neuro-Oncology.

[38]  P. Schürmann,et al.  C‐MYC expression in medulloblastoma and its prognostic value , 2000, International journal of cancer.

[39]  M. Berger,et al.  The risks of metastases from shunting in children with primary central nervous system tumors. , 1991, Journal of neurosurgery.

[40]  C. Kruchko,et al.  CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. , 2012, Neuro-oncology.

[41]  S. Marie,et al.  Extraneural metastases in medulloblastoma. , 2011, Arquivos de neuro-psiquiatria.

[42]  D. Birnbaum,et al.  BMC Cancer , 2003 .